ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet Hematology
June 03, 2024 08:00 ET
|
Oryzon Genomics, S.A.
The Phase IIa study ALICE evaluated the combination of iadademstat plus azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML)The combination showed substantial antileukemic...
ORYZON to Provide Corporate Progress Updates at Several Events in June
May 30, 2024 08:00 ET
|
Oryzon Genomics, S.A.
BIO International Convention 2024European Hematology Association (EHA) 2024 European Network to Cure ALS (ENCALS) 2024 MADRID and CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Oryzon...
ORYZON Selected as Associated Partner in the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
May 29, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Commission has approved up to €1 billion of State aid by six Member States: Belgium, France, Hungary, Italy, Slovakia, and SpainOryzon to validate epigenetic agents by applying a personalized medicine...
ORYZON to Provide Corporate Progress Updates at Several Events in May
May 09, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Bio-Equity Europe 2024Asebio Investor Day 2024RSC Hot Topics: Covalent Drug DiscoveryForo Medcap BME 2024 MADRID, Spain and CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A....
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2024
May 06, 2024 12:03 ET
|
Oryzon Genomics, S.A.
Finalizing full data analysis from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) Company planning to request an End-of-Phase II meeting with the FDA to discuss plans...
ORYZON Secures Another Important Patent for its Lead CNS Asset, Vafidemstat
April 22, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Has received “Intention to Grant” from the European Patent Office For the treatment of aggression and social withdrawal MADRID, Spain and CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Oryzon...
ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
April 08, 2024 08:00 ET
|
Oryzon Genomics, S.A.
MADRID, Spain and CAMBRIDGE, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to...
ORYZON to Provide Corporate Progress Updates at Several Events in April
April 05, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Investing in Oncology Forum 2024Van Lanschot Kempen Life Sciences Conference Swiss Biotech Day 2024LSX World Congress MADRID, Spain and BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics,...
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023
February 26, 2024 14:28 ET
|
Oryzon Genomics, S.A.
Topline data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD) reported with promising results in secondary endpoints of overall severity and control of...
ORYZON to Provide Corporate Progress Updates at Several Events in February-March
February 05, 2024 08:00 ET
|
Oryzon Genomics, S.A.
Keystone Symposia Epigenetic Mechanisms and Cancer TreatmentBio-Neuroscience17th Annual European Life Sciences CEO Forum BIO-Europe Spring 2024 MADRID, Spain and BOSTON, Feb. 05, 2024 (GLOBE...